Filters close
Newswise: Exercise boosts anti-cancer immunity and reduces inflammation in Lynch Syndrome patients
19-Sep-2023 6:00 AM EDT
Exercise boosts anti-cancer immunity and reduces inflammation in Lynch Syndrome patients
University of Texas MD Anderson Cancer Center

Regular and intense aerobic exercise may reduce the risk of colorectal cancer in patients with Lynch Syndrome (LS) by improving the immune system's ability to detect and remove potentially harmful cells, according to researchers at The University of Texas MD Anderson Cancer Center.

   
Newswise: Research identifies new potential hurdle for nano-based therapies
17-Sep-2023 8:00 PM EDT
Research identifies new potential hurdle for nano-based therapies
University of Texas MD Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body’s ability to respond to treatment.

Newswise: Combination immunotherapy treatment effective before lung cancer surgery
13-Sep-2023 2:00 PM EDT
Combination immunotherapy treatment effective before lung cancer surgery
University of Texas MD Anderson Cancer Center

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

Newswise: Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancer
11-Sep-2023 3:00 PM EDT
Intensity-modulated radiation therapy provides long-term benefits to patients with locally advanced lung cancer
University of Texas MD Anderson Cancer Center

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.

1-Sep-2023 11:05 AM EDT
Enhanced recovery program successfully reduced opioid use after pancreatic cancer surgery
University of Texas MD Anderson Cancer Center

By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid use by 50% after pancreatic cancer surgery and cut the median opioid prescription volumes at discharge to zero.

Released: 6-Sep-2023 8:00 AM EDT
MD Anderson and Panacea launch Manaolana Oncology to develop antibody-based therapies for cancer
University of Texas MD Anderson Cancer Center

MD Anderson and Panacea Venture announced the launch of Manaolana Oncology, a new company created to develop and advance antibody-based therapies against novel cancer targets.

Released: 30-Aug-2023 12:00 PM EDT
MD Anderson Research Highlights for August 30, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a novel computational tool to detect single base pair DNA changes in single-cell sequencing data, a potential target to treat hypertension caused by drugs commonly used in organ transplants, further insights into the steps involved in genetic recombination, a novel treatment target for a subset of adenoid cystic carcinoma (ACC), a combination therapy that improves outcomes in certain patients with acute myeloid leukemia (AML), and a target for treating prolonged cytopenia in patients with relapsed/refractory large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapy.

   
Newswise: Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models
22-Aug-2023 5:05 PM EDT
Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models
University of Texas MD Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.

   
Newswise: MD Anderson receives nearly $4.9 million in CPRIT funding for cancer prevention programs and recruitment
Released: 17-Aug-2023 8:50 AM EDT
MD Anderson receives nearly $4.9 million in CPRIT funding for cancer prevention programs and recruitment
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center was awarded four grants totaling nearly $4.9 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the expansion of physical activity programs for survivors, the dissemination of targeted tobacco cessation programs and the recruitment of a first-time, tenure-track faculty member.

Released: 16-Aug-2023 12:15 PM EDT
MD Anderson Research Highlights for August 16, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
Newswise: University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
Released: 14-Aug-2023 4:35 PM EDT
University of Texas System Regents announce plans to build UT Medical Center on site of Erwin Center
University of Texas MD Anderson Cancer Center

Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative to accelerate and expand UT Austin’s burgeoning medical district into a world-class academic medical center for education, research and patient care. The University of Texas at Austin Medical Center will start with two new hospital towers -- The University of Texas MD Anderson Cancer Center and a UT Austin hospital. MD Anderson, the nation’s #1 cancer hospital, will expand its Houston footprint to Austin by building and operating a new, comprehensive cancer center, while UT Austin will build and operate its new specialty hospital.

Newswise: MD Anderson names Christopher Flowers, M.D., Division Head of Cancer Medicine
Released: 2-Aug-2023 4:05 PM EDT
MD Anderson names Christopher Flowers, M.D., Division Head of Cancer Medicine
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, M.D., an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search. His appointment is effective Sept. 1.

Released: 2-Aug-2023 12:00 PM EDT
MD Anderson Research Highlights for August 2, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.

Released: 1-Aug-2023 12:05 AM EDT
MD Anderson ranked #1 in the nation for cancer care
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2023-24 “Best Hospitals” survey. The institution has been one of the nation’s top two hospitals for cancer care since the survey’s inception in 1990.

26-Jul-2023 12:40 PM EDT
Lost metabolic fitness of CAR NK cells is key mechanism of tumor resistance
University of Texas MD Anderson Cancer Center

A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.

Released: 26-Jul-2023 8:00 AM EDT
MD Anderson and Nexo Therapeutics announce strategic research collaboration to advance new therapies against intractable targets
University of Texas MD Anderson Cancer Center

MD Anderson and Nexo announced a strategic research collaboration to rapidly advance new cancer therapies against previously undruggable targets.

Released: 19-Jul-2023 12:00 PM EDT
MD Anderson Research Highlights for July 19, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

   
Newswise: Howard and Susan Elias make $16.25 million gift to fund cancer neuroscience research at MD Anderson
18-Jul-2023 9:00 AM EDT
Howard and Susan Elias make $16.25 million gift to fund cancer neuroscience research at MD Anderson
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today announced a $16.25 million gift from Howard and Susan Elias to accelerate brain tumor and cancer neuroscience research, an emerging field focused on integrating the role of the nervous system in cancer.

Newswise: New single-cell study provides novel insights into gastric cancer
6-Jul-2023 10:40 AM EDT
New single-cell study provides novel insights into gastric cancer
University of Texas MD Anderson Cancer Center

A single-cell study led by MD Anderson researchers and published in Cancer Cell provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.

27-Jun-2023 4:00 PM EDT
Blood test aids in predicting lung cancer mortality risk
University of Texas MD Anderson Cancer Center

A blood-based four-protein panel (4MP), when combined with a lung cancer risk model (PLCOm2012), can better identify those at high risk of dying from lung cancer than the current U.S. Preventive Services Task Force (USPSTF) criteria.

Newswise: Largest-ever atlas of normal breast cells brings unprecedented insights into mammary biology
26-Jun-2023 4:05 PM EDT
Largest-ever atlas of normal breast cells brings unprecedented insights into mammary biology
University of Texas MD Anderson Cancer Center

A new study led by researchers at The University of Texas MD Anderson Cancer, University of California, Irvine and Baylor College of Medicine has created the world’s largest and most comprehensive map of normal breast tissue, providing an unprecedented understanding of mammary biology that may help identify therapeutic targets for diseases such as breast cancer. The Human Breast Cell Atlas, published today in Nature, used single-cell and spatial genomic methods to profile more than 714,000 cells from 126 women. The breast atlas highlights 12 major cell types and 58 biological cell states, and identifies differences based on ethnicity, age and the menopause status of healthy women.

Released: 27-Jun-2023 3:00 PM EDT
MD Anderson Research Highlights for June 27, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
Newswise: New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers
25-Jun-2023 11:00 AM EDT
New understanding of why kidney cancers become metastatic discovered by MD Anderson researchers
University of Texas MD Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression. The study, published today in Nature Cancer, demonstrates that the loss of a cluster of interferon receptor (IFNR) genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability. This genomic feature may be used to help clinicians predict a tumor’s potential to become metastatic and treatment resistant.

Newswise: MD Anderson and Ochsner Health announce partnership to create first fully integrated cancer program in Louisiana
Released: 22-Jun-2023 12:30 PM EDT
MD Anderson and Ochsner Health announce partnership to create first fully integrated cancer program in Louisiana
University of Texas MD Anderson Cancer Center

MD Anderson and Ochsner Health announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Cancer patients in the region now have access to cancer treatments that are among the most advanced in the nation.

Newswise: Mutant KRAS regulates Y chromosome gene in colorectal cancer, driving metastasis and inhibiting anti-tumor immunity
20-Jun-2023 2:05 PM EDT
Mutant KRAS regulates Y chromosome gene in colorectal cancer, driving metastasis and inhibiting anti-tumor immunity
University of Texas MD Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a gene on the Y chromosome that is upregulated in KRAS-mutated colorectal cancer (CRC), increasing tumor cell invasiveness and reducing anti-tumor immunity in male patients.

Released: 20-Jun-2023 7:00 AM EDT
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
University of Texas MD Anderson Cancer Center

MD Anderson and Replay announced that the FDA has issued a 'safe to proceed' for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.

Newswise: Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
15-Jun-2023 4:00 PM EDT
Adagrasib effective for patients with KRAS G12C-mutant lung cancer and untreated brain metastases
University of Texas MD Anderson Cancer Center

Researchers at The University of Texas MD Anderson Cancer Center found the KRAS G12C inhibitor adagrasib showed promising activity suppressing cancer growth not only within the lungs but also in brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer.

15-Jun-2023 2:20 PM EDT
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Newswise: Study brings new understanding of multiple myeloma evolution
9-Jun-2023 1:45 PM EDT
Study brings new understanding of multiple myeloma evolution
University of Texas MD Anderson Cancer Center

A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma from precursor disease, which may help better identify patients likely to progress and develop new interventions

Released: 7-Jun-2023 12:00 PM EDT
MD Anderson Research Highlights for June 7, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
4-Jun-2023 11:00 AM EDT
ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma
University of Texas MD Anderson Cancer Center

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

Newswise: ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
1-Jun-2023 10:35 AM EDT
ASCO: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
University of Texas MD Anderson Cancer Center

Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.

Newswise: ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types
2-Jun-2023 4:10 PM EDT
ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types
University of Texas MD Anderson Cancer Center

In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study, led by The University of Texas MD Anderson Cancer Center, were presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Newswise: ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
31-May-2023 3:20 PM EDT
ASCO: Targeted therapy induces responses in HER2-amplified biliary tract cancer
University of Texas MD Anderson Cancer Center

An MD Anderson-led Phase II trial showed the HER2-targeted therapy zanidatamab demonstrated durable responses in patients with advanced HER2-positive biliary tract cancer. The data were presented at the 2023 ASCO Annual Meeting.

Newswise: Pan-cancer T cell atlas reveals new details of tumor microenvironment
26-May-2023 9:55 AM EDT
Pan-cancer T cell atlas reveals new details of tumor microenvironment
University of Texas MD Anderson Cancer Center

A new study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, provides a deeper understanding of the vast diversity of T cell states as well as their relationships and roles within the complex tumor microenvironment, bringing a fresh perspective to understanding immunotherapy efficacy in cancer.

Released: 25-May-2023 5:00 PM EDT
MD Anderson Research Highlights: ASCO 2023 Special Edition
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

   
24-May-2023 3:05 PM EDT
ASCO: Luspatercept enables majority of patients with MDS to end reliance on blood transfusions
University of Texas MD Anderson Cancer Center

Treatment with luspatercept improved red blood cell counts and erythroid responses compared to treatment with epoetin alfa in patients with myelodysplastic syndromes (MDS), allowing the majority to no longer require regular blood transfusions. Results from the Phase III COMMANDS trial, led by researchers at The University of Texas MD Anderson Cancer Center, were reported at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Released: 24-May-2023 12:00 PM EDT
MD Anderson Research Highlights for May 24, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
15-May-2023 2:40 PM EDT
MD Anderson awarded over $5.7 million from Break Through Cancer to support AML research
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in acute myeloid leukemia (AML) and to treat clonal hematopoiesis, a precursor to AML.

Newswise: Combined delivery of engineered virus with immunotherapy is safe and improves outcomes in subset of patients with glioblastoma
15-May-2023 11:00 AM EDT
Combined delivery of engineered virus with immunotherapy is safe and improves outcomes in subset of patients with glioblastoma
University of Texas MD Anderson Cancer Center

Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional Phase I/II clinical trial co-led by researchers at The University of Texas MD Anderson Cancer Center and the University of Toronto.

   
Released: 10-May-2023 2:00 PM EDT
MD Anderson Research Highlights for May 10, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

   
Released: 10-May-2023 10:00 AM EDT
Allison Institute announces appointment of inaugural members
University of Texas MD Anderson Cancer Center

The James P. Allison Institute at MD Anderson announced the appointment of seven inaugural members to lead groundbreaking research and bring the benefits of immunotherapy to all patients.

Newswise: MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences
Released: 3-May-2023 2:55 PM EDT
MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences
University of Texas MD Anderson Cancer Center

Two MD Anderson researchers, Helen Piwnica-Worms, Ph.D., and Richard Wood, Ph.D., have been elected to the prestigious National Academy of Sciences for their respective contributions to advancing our understanding of cancer genetics, biochemistry and cell biology.

Released: 27-Apr-2023 8:00 AM EDT
MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI
University of Texas MD Anderson Cancer Center

MD Anderson and Generate:Biomedicines announced a co-development and commercialization agreement to accelerate novel protein therapies using generative AI.

   
Released: 26-Apr-2023 11:00 AM EDT
MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology
University of Texas MD Anderson Cancer Center

The American Society of Clinical Oncology (ASCO) will present the 2023 David A. Karnofsky Memorial Award to Hagop Kantarjian, M.D., chair of Leukemia at The University of Texas MD Anderson Cancer Center, for his contributions to leukemia clinical research and his dedication to improving the lives of patients.

19-Apr-2023 4:35 PM EDT
Cancer survivor gives $10 million to speed translational research and clinical trials
University of Texas MD Anderson Cancer Center

Vijay Goradia, a Houston-based businessman, philanthropist, and cancer survivor, has donated $10 million to The University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.

Released: 19-Apr-2023 12:00 PM EDT
MD Anderson Research Highlights for April 19, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

   
Newswise: AACR: Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
17-Apr-2023 10:30 AM EDT
AACR: Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
University of Texas MD Anderson Cancer Center

In a new study, researchers from The University of Texas MD Anderson Cancer Center created the largest single-cell atlas of brain metastases from renal cell carcinoma (RCC) with matched primary and extracranial metastases, enabling the discovery of key biological mechanisms driving an immunosuppressive tumor microenvironment in the brain distinct from that of the kidney or other metastatic sites.

   
Newswise: AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
14-Apr-2023 12:05 PM EDT
AACR: Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023. The studies, which describe results from a novel FGFR inhibitor and from new PARP/ATR inhibitor combinations, were featured in a plenary session highlighting novel biomarker-driven molecularly targeted therapy trials.

Newswise: AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
13-Apr-2023 3:35 PM EDT
AACR: Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
University of Texas MD Anderson Cancer Center

A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations in three tumor suppressor genes – KEAP1, SMARCA4 and CDKN2A – are linked with poor clinical outcomes in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitors adagrasib or sotorasib.



close
0.24337